A prospective study of plasma adiponectin levels and prostate cancer risk and survival.

A199 A prospective study of plasma adiponectin levels and prostate cancer risk and survival ABSTRACT Background: Obesity/Overweight is associated with metastatic and fatal prostate cancer and predicts poor survival; it thus may play a significant role in cancer progression. Adiponectin is an adipocyte-derived cytokine, and its circulating levels are inversely correlated with adiposity. At physiological concentrations, adiponectin inhibits in vitro cell growth of both the androgen-dependent and androgen-independent prostate cancer cell lines, and might therefore be beneficial. However, human data is very sparse. Methods: In the Physicians9 Health Study, after excluding men who reported diabetes at the baseline, 610 cases and 583 age-matched controls were available for the analyses. We examined the associations of prediagnostic plasma adiponectin levels with prostate cancer incidence among 583 case-control pairs (1:1), using conditional logistic regression. Of these cases, 194 men had high-grade (Gleason 7-10 or poorly differentiated) tumor and 117 men had lethal disease, defined as stage D at diagnosis, or developed metastases or died of prostate cancer during the follow-up by 2005. We further applied Cox proportional hazards models to assess the role of adiponectin in prostate cancer survival among 610 cases. Results: Adiponectin levels were inversely correlated with baseline body mass index (BMI, correlation coefficient, r = -0.18, P